Media Room

For More Information Contact

For Media Inquiries:

Dana Korsen
Phone:
202-334-2183
Fax:
202-334-2843
E-mail:
dkorsen@nas.edu

Mailing Address

The National Academies of Sciences, Engineering, and Medicine

Health and Medicine Division

500 Fifth St, NW
Washington, DC 20001

Selected Filters

Filter News

News and Announcements

The latest news from HMD, including information about new reports, activities, meetings, and other noteworthy events.


News Release

Press Release: Urgent Change Needed to Improve Diagnosis in Health Care or Diagnostic Errors Will Likely Worsen, Says New Report
Released: 9/22/2015

Most people will experience at least one diagnostic error -- an inaccurate or delayed diagnosis -- in their lifetime, sometimes with devastating consequences, says a new report from the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine.

Report at a Glance

  • Figures (HTML)
  • Report in Brief (PDF)
  • List of Recommendations (PDF)
  • Resources for Improving Communication (PDF)
  • Resources for Improving Communication (Spanish) (PDF)
  • Cover Image and Citation Slide (HTML)
Reports: Related Reports
Activities: Related Activities

News Release

Health Care Wait Times Vary Greatly Throughout U.S.; New IOM Report Calls for Putting Patients and Families First Using Approaches Applied Successfully in Other Sectors
Released: 6/29/2015

Tremendous variability in wait times for health care appointments exists throughout the U.S., ranging from same day service to several months, says a new report from the Institute of Medicine.

Report at a Glance

  • Report Brief (PDF)
  • Key-Findings-Recommendations (PDF)
  • Key Principles (PDF)
Reports: Related Reports
Activities: Related Activities

News Release

IOM Report Details Strategy for Monitoring Safety of Childhood Immunization Schedule
Released: 1/16/2013

A review of the available evidence underscores the safety of the federal childhood immunization schedule, says a new report from the Institute of Medicine. Should signals indicate the need for investigation of the schedule, however, the report offers a framework for conducting safety research using existing or new data collection systems.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

News Release

Institute of Medicine Receives $750,000 Gift to Establish Omenn Fellowship
Released: 1/4/2013

Gilbert S. Omenn and Martha Darling have made a gift of $750,000 to the Institute of Medicine to create a permanent two-year biomedical science and public policy or population-based medicine fellowship. The Omenn Fellowship is the newest addition to the Institute of Medicine Anniversary Fellows program, which provides early-career health science scholars with the opportunity to participate in evidence-based health care or public health policy studies that improve the nation's health.

Reports: Related Reports
Activities: Related Activities

News Release

Independent Review Commends CIRM's Achievements, But Calls on Institute to Revise Governance and Policies to Maintain Credibility and Impact
Released: 12/6/2012

The California Institute for Regenerative Medicine (CIRM) has achieved many notable results during its first seven years and helped establish the state of California as an international hub of stem cell research and development, says a new report from the Institute of Medicine. However, CIRM's efforts could be enhanced by creating an external scientific advisory board to provide continuing and consistent strategic advice, by dealing more effectively with the perception of conflicts of interest on its governing board, and by reorganizing its governance to ensure that the board is able to provide independent oversight.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

News Release

Creation of a Central Management Plan for Every New Drug Needed to Strengthen FDA's Oversight of Approved Drugs' Safety
Released: 5/1/2012

Although the approval of a new drug is based on evidence that its benefits outweigh its risks, the full range of a medication's effects may not become apparent until a product has been used by a larger, more diverse population over an extended period of time. Problems associated with the anti-diabetes drug Avandia, pain reliever Vioxx, and cholesterol-reducing drug Crestor illustrate the challenges and underscore the need for a more systematic and transparent process to collect, assess, and act on data about a medication's benefit-risk profile throughout its entire "life cycle" from approval until it is no longer marketed, says a new report by the Institute of Medicine.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

News Release

IOM Report Recommends Evaluation and Validation Process to Prevent Problems Associated With Turning 'Omics' Research Into Clinical Tests
Released: 3/23/2012

Genomics, proteomics, and other branches of molecular bioscience offer the prospect of greater precision in medical care, but some clinical tests based on "omics" research have proved invalid and highlighted the challenges of dealing with complex data. To enhance the translation of omics-based discoveries to clinical use, a new report by the Institute of Medicine recommends a detailed process to evaluate whether the data and computational steps underlying such tests are sound and the tests are ready to be used in clinical trials. The proposed process defines responsibilities and best practices for the investigators, research institutions, funders, regulators, and journals involved in development and dissemination of clinical omics-based technologies.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

News Release

Federal Laws Have Enhanced Pediatric Drug Studies; IOM Report Identifies Options for Further Improvements
Released: 2/29/2012

Federal laws that motivate or require drug and biologic developers to conduct pediatric studies have yielded beneficial information to guide the use of medications in children, says a new report by the Institute of Medicine. Still, studies involving children continue to be limited, especially in certain areas such as medications' use in newborns and long-term safety and effectiveness in children.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

News Release

IOM Report Recommends Stringent Limits on Use of Chimpanzees in Biomedical and Behavioral Research
Released: 12/15/2011

Given that chimpanzees are so closely related to humans and share similar behavioral traits, the National Institutes of Health should allow their use as subjects in biomedical research only under stringent conditions, including the absence of any other suitable model and inability to ethically perform the research on people, says a new report from the Institute of Medicine and National Research Council. In addition, use of these animals should be permissible only if forgoing their use will prevent or significantly hinder advances necessary to prevent or treat life-threatening or debilitating conditions, said the committee that wrote the report. Based on these criteria, chimpanzees are not necessary for most biomedical research.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

News Release

IOM Elects 65 New Members, Five Foreign Associates
Released: 10/17/2011

The IOM announced the names of 65 new members and five foreign associates on October 17 in conjunction with its 41st annual meeting. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

Reports: Related Reports
Activities: Related Activities